Voya Investment Management LLC Sells 2,335,093 Shares of Elanco Animal Health Incorporated $ELAN

Voya Investment Management LLC cut its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 97.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 60,007 shares of the company’s stock after selling 2,335,093 shares during the period. Voya Investment Management LLC’s holdings in Elanco Animal Health were worth $1,209,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. Jennison Associates LLC grew its holdings in shares of Elanco Animal Health by 322.0% in the 2nd quarter. Jennison Associates LLC now owns 3,234,717 shares of the company’s stock worth $46,192,000 after purchasing an additional 2,468,122 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Elanco Animal Health by 104.5% during the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock worth $50,268,000 after purchasing an additional 2,445,872 shares during the period. Primecap Management Co. CA raised its position in shares of Elanco Animal Health by 3.1% in the 2nd quarter. Primecap Management Co. CA now owns 51,766,814 shares of the company’s stock valued at $739,230,000 after acquiring an additional 1,543,279 shares during the period. Norges Bank bought a new stake in Elanco Animal Health in the second quarter valued at approximately $12,502,000. Finally, Brandes Investment Partners LP increased its position in shares of Elanco Animal Health by 11.3% in the 2nd quarter. Brandes Investment Partners LP now owns 8,100,322 shares of the company’s stock valued at $115,673,000 after buying an additional 820,901 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, insider Rajeev A. Modi bought 4,500 shares of the stock in a transaction that occurred on Thursday, December 11th. The stock was acquired at an average cost of $21.33 per share, with a total value of $95,985.00. Following the transaction, the insider directly owned 123,082 shares in the company, valued at approximately $2,625,339.06. This trade represents a 3.79% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Lawrence Erik Kurzius purchased 10,000 shares of the company’s stock in a transaction dated Friday, December 12th. The stock was purchased at an average price of $21.30 per share, for a total transaction of $213,000.00. Following the transaction, the director directly owned 131,773 shares in the company, valued at approximately $2,806,764.90. This trade represents a 8.21% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have acquired 43,450 shares of company stock valued at $937,883. Company insiders own 0.89% of the company’s stock.

Elanco Animal Health Trading Up 0.5%

ELAN opened at $22.75 on Wednesday. The company’s 50 day moving average is $22.14 and its 200-day moving average is $18.82. The company has a market cap of $11.30 billion, a P/E ratio of 379.26, a PEG ratio of 3.47 and a beta of 1.86. Elanco Animal Health Incorporated has a 1-year low of $8.02 and a 1-year high of $23.70. The company has a current ratio of 2.40, a quick ratio of 1.23 and a debt-to-equity ratio of 0.59.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.06. The company had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.09 billion. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The company’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.13 earnings per share. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. Equities research analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on ELAN shares. Wall Street Zen cut Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Saturday, December 20th. Stifel Nicolaus upped their price objective on Elanco Animal Health from $18.00 to $23.00 and gave the company a “buy” rating in a research note on Wednesday, September 24th. UBS Group upped their target price on Elanco Animal Health from $25.00 to $27.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. KeyCorp reiterated an “overweight” rating on shares of Elanco Animal Health in a research note on Wednesday, December 10th. Finally, Barclays assumed coverage on Elanco Animal Health in a report on Tuesday, December 9th. They issued an “overweight” rating and a $30.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $23.78.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.